260 related articles for article (PubMed ID: 26810548)
1. Effects of soybean ingestion on pharmacokinetics of levodopa and motor symptoms of Parkinson's disease--In relation to the effects of Mucuna pruriens.
Nagashima Y; Kondo T; Sakata M; Koh J; Ito H
J Neurol Sci; 2016 Feb; 361():229-34. PubMed ID: 26810548
[TBL] [Abstract][Full Text] [Related]
2. Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease.
Müller T; Kolf K; Ander L; Woitalla D; Muhlack S
Clin Neuropharmacol; 2008; 31(3):134-40. PubMed ID: 18520980
[TBL] [Abstract][Full Text] [Related]
3. Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study.
Katzenschlager R; Evans A; Manson A; Patsalos PN; Ratnaraj N; Watt H; Timmermann L; Van der Giessen R; Lees AJ
J Neurol Neurosurg Psychiatry; 2004 Dec; 75(12):1672-7. PubMed ID: 15548480
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 200 mg retarded release levodopa/carbidopa - with 150 mg levodopa/carbidopa/entacapone application: pharmacokinetics and efficacy in patients with Parkinson's disease.
Müller T; Ander L; Kolf K; Woitalla D; Muhlack S
J Neural Transm (Vienna); 2007; 114(11):1457-62. PubMed ID: 17564755
[TBL] [Abstract][Full Text] [Related]
5. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
[TBL] [Abstract][Full Text] [Related]
6. Daily intake of Mucuna pruriens in advanced Parkinson's disease: A 16-week, noninferiority, randomized, crossover, pilot study.
Cilia R; Laguna J; Cassani E; Cereda E; Raspini B; Barichella M; Pezzoli G
Parkinsonism Relat Disord; 2018 Apr; 49():60-66. PubMed ID: 29352722
[TBL] [Abstract][Full Text] [Related]
7. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients.
Stocchi F; Hsu A; Khanna S; Ellenbogen A; Mahler A; Liang G; Dillmann U; Rubens R; Kell S; Gupta S
Parkinsonism Relat Disord; 2014 Dec; 20(12):1335-40. PubMed ID: 25306200
[TBL] [Abstract][Full Text] [Related]
8. Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations.
Contin M; Lopane G; Passini A; Poli F; Iannello C; Guarino M
Clin Neuropharmacol; 2015; 38(5):201-3. PubMed ID: 26366963
[TBL] [Abstract][Full Text] [Related]
9. Mucuna pruriens for Parkinson's disease: Low-cost preparation method, laboratory measures and pharmacokinetics profile.
Cassani E; Cilia R; Laguna J; Barichella M; Contin M; Cereda E; Isaias IU; Sparvoli F; Akpalu A; Budu KO; Scarpa MT; Pezzoli G
J Neurol Sci; 2016 Jun; 365():175-80. PubMed ID: 27206902
[TBL] [Abstract][Full Text] [Related]
10. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease.
Müller T; Erdmann C; Muhlack S; Bremen D; Przuntek H; Goetze O; Woitalla D
J Neural Transm (Vienna); 2006 Oct; 113(10):1441-8. PubMed ID: 16604302
[TBL] [Abstract][Full Text] [Related]
12. Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules.
Modi NB; Mittur A; Rubens R; Khanna S; Gupta S
Clin Neuropharmacol; 2019; 42(1):4-8. PubMed ID: 30520758
[TBL] [Abstract][Full Text] [Related]
13.
Cilia R; Laguna J; Cassani E; Cereda E; Pozzi NG; Isaias IU; Contin M; Barichella M; Pezzoli G
Neurology; 2017 Aug; 89(5):432-438. PubMed ID: 28679598
[TBL] [Abstract][Full Text] [Related]
14. Levodopa/carbidopa microtablets in Parkinson's disease: a study of pharmacokinetics and blinded motor assessment.
Senek M; Aquilonius SM; Askmark H; Bergquist F; Constantinescu R; Ericsson A; Lycke S; Medvedev A; Memedi M; Ohlsson F; Spira J; Westin J; Nyholm D
Eur J Clin Pharmacol; 2017 May; 73(5):563-571. PubMed ID: 28101657
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.
Müller T
Clin Neuropharmacol; 2013; 36(3):84-91. PubMed ID: 23673910
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease.
Safirstein BE; Ellenbogen A; Zhao P; Henney HR; Kegler-Ebo DM; Oh C
Clin Ther; 2020 Jun; 42(6):1034-1046. PubMed ID: 32482490
[TBL] [Abstract][Full Text] [Related]
17. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease.
Verhagen Metman L; Stover N; Chen C; Cowles VE; Sweeney M
Mov Disord; 2015 Aug; 30(9):1222-8. PubMed ID: 25847690
[TBL] [Abstract][Full Text] [Related]
18. Opicapone Pharmacokinetics and Effects on Catechol- O -Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/Levodopa.
LeWitt P; Liang GS; Olanow CW; Kieburtz KD; Jimenez R; Olson K; Klepitskaya O; Loewen G
Clin Neuropharmacol; 2023 Mar-Apr 01; 46(2):43-50. PubMed ID: 36688497
[TBL] [Abstract][Full Text] [Related]
19. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
Fung VS; Herawati L; Wan Y; ;
Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
[TBL] [Abstract][Full Text] [Related]
20. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease.
LeWitt PA; Huff FJ; Hauser RA; Chen D; Lissin D; Zomorodi K; Cundy KC
Mov Disord; 2014 Jan; 29(1):75-82. PubMed ID: 24339234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
